Stocktoria

Indivior Pharmaceuticals, Inc. INDV

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-06-12 · LEI

Indivior Pharmaceuticals, Inc. statistics & valuation

Market cap$5.1B
P / E24.3×
P / S4.1×
Net margin16.9%
FCF margin-7.5%
Net debt$95.0M
Net debt / EBITDA0.3×
Enterprise value USD$5.2B
EV / EBITDA19.1×
Earnings yield EBIT/EV5%
Return on capital91.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-11.50% 0.60% 16.90% 202320242025
Gross margin (%)
84.10% 80.60% 80.20% 202320242025
Operating margin (%)
-13.90% 3.20% 21.10% 202320242025
Return on equity (%)
202320242025
Shares outstanding
137.0M 133.0M 128.0M 202320242025
Net debt ($)
-$79.0M -$4.0M $95.0M 202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-7.20% 0.50% 17.50% 202320242025
Free cash flow margin (%)
-28.20% 0.60% -7.50% 202320242025
Debt / equity (×)
202320242025
EPS ($)
-$0.92 $0.05 $1.64 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Gross margin80.2%80.6%84.1%
Operating margin21.1%3.2%-13.9%
Net margin16.9%0.6%-11.5%
FCF margin-7.5%0.6%-28.2%
Return on assets17.5%0.5%-7.2%
Return on equity-214.3%-2.1%68.5%
Debt / equity-2.96×-0.93×-1.29×
Current ratio0.710.900.98

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.